Paul L. Berns, President and CEO at Anacor Pharmaceuticals, Inc. (ANAC), sold 25,000 shares at $30.82 ($771K) on 2014-12-26, disclosed to the SEC on 2014-12-29.
Scheduled sale ($770k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| NMRA | SELL | 2026-02-19 | $34K | — | Filing → |
| NMRA | SELL | 2025-02-20 | $23K | — | Filing → |
| MTSR | BUY | 2025-02-03 | $14.2M | — | Filing → |